AU2021306709A1 - Antigen binding molecules targeting SARS-CoV-2 - Google Patents

Antigen binding molecules targeting SARS-CoV-2 Download PDF

Info

Publication number
AU2021306709A1
AU2021306709A1 AU2021306709A AU2021306709A AU2021306709A1 AU 2021306709 A1 AU2021306709 A1 AU 2021306709A1 AU 2021306709 A AU2021306709 A AU 2021306709A AU 2021306709 A AU2021306709 A AU 2021306709A AU 2021306709 A1 AU2021306709 A1 AU 2021306709A1
Authority
AU
Australia
Prior art keywords
seq
polypeptide
antibody
cov
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021306709A
Other languages
English (en)
Inventor
Ross Steven FEDERMAN
Robin Jeffrey GREEN
Gevorg GRIGORYAN
John Ingraham
Cheuk Lun Leung
Alexis Hiram Ramos
Jenhan TAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flagship Pioneering Innovations VI Inc
Original Assignee
Flagship Pioneering Innovations VI Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations VI Inc filed Critical Flagship Pioneering Innovations VI Inc
Publication of AU2021306709A1 publication Critical patent/AU2021306709A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021306709A 2020-07-06 2021-07-06 Antigen binding molecules targeting SARS-CoV-2 Pending AU2021306709A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063048589P 2020-07-06 2020-07-06
US63/048,589 2020-07-06
US202063070035P 2020-08-25 2020-08-25
US63/070,035 2020-08-25
PCT/US2021/040546 WO2022010921A1 (en) 2020-07-06 2021-07-06 Antigen binding molecules targeting sars-cov-2

Publications (1)

Publication Number Publication Date
AU2021306709A1 true AU2021306709A1 (en) 2023-02-09

Family

ID=77127097

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021306709A Pending AU2021306709A1 (en) 2020-07-06 2021-07-06 Antigen binding molecules targeting SARS-CoV-2

Country Status (8)

Country Link
US (1) US11981725B2 (https=)
EP (1) EP4175983A1 (https=)
JP (1) JP2023534923A (https=)
KR (1) KR20230035350A (https=)
AU (1) AU2021306709A1 (https=)
CA (1) CA3183367A1 (https=)
IL (1) IL299630A (https=)
WO (1) WO2022010921A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022010912A1 (en) 2020-07-06 2022-01-13 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting sars-cov-2
CA3183367A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
CN116528897A (zh) 2020-08-26 2023-08-01 旗舰开拓创新六世公司 靶向SARS-CoV-2的抗原结合分子
WO2023173577A1 (zh) * 2022-03-15 2023-09-21 慧壹科技(上海)有限公司 冠状病毒抗体及其用途
EP4519310A1 (en) 2022-05-06 2025-03-12 Generate Biomedicines, Inc. Antigen binding molecules targeting sars-cov-2
WO2024102674A1 (en) 2022-11-13 2024-05-16 Generate Biomedicines, Inc. Antigen binding molecules targeting sars-cov-2

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG128680A1 (en) * 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
CA2548942C (en) 2003-12-05 2013-10-15 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Anti-sars monoclonal antibodies
US8106170B2 (en) * 2004-11-11 2012-01-31 Crucell Holland B.V. Compositions against SARS-coronavirus and uses thereof
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
HRP20150279T1 (hr) 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
UA119328C2 (uk) 2013-08-09 2019-06-10 Астеллас Фарма Інк. Антитіло до тslp-рецептора людини
CN108064243B (zh) 2014-10-01 2021-08-27 免疫医疗有限公司 对lox1具有特异性的结合蛋白及其用途
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
WO2020180398A1 (en) 2019-01-14 2020-09-10 The Regents Of The University Of California Compositions and methods for modulating cellular internalization
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
JP2023512684A (ja) 2020-02-03 2023-03-28 ヴィア・バイオテクノロジー・インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２に対する抗体およびそれを使用する方法
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
BR112022017048A2 (pt) 2020-02-26 2022-11-16 Vir Biotechnology Inc Anticorpos contra sars-cov-2 e métodos para usar os mesmos
EP4121454A1 (en) * 2020-03-19 2023-01-25 Imperial College Innovations Limited Coronavirus antibody
US11028167B1 (en) 2020-03-23 2021-06-08 Centivax, Inc. Anti-SARS-Cov-2 antibodies derived from 3bgf
KR20250107297A (ko) 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
WO2021203053A1 (en) 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunotherapy targeting a conserved region in sars coronaviruses
US20230348571A1 (en) 2020-04-06 2023-11-02 Vanderbilt University Cross-reactive coronavirus antibodies and uses thereof
JP2023521418A (ja) 2020-04-10 2023-05-24 インビビド， インコーポレイテッド コロナウイルスｓタンパク質に特異的な化合物及びその使用
US20240059757A1 (en) 2020-04-14 2024-02-22 Vir Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
US20230174628A1 (en) 2020-04-28 2023-06-08 Peking University Anti-novel coronavirus monoclonal antibody and application thereof
WO2021226560A1 (en) 2020-05-08 2021-11-11 Vir Biotechnology, Inc. Antibodies against sars-cov-2
WO2021247925A1 (en) 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Structure-guided immunotherapy against sars-cov-2
WO2022010912A1 (en) 2020-07-06 2022-01-13 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting sars-cov-2
CA3183367A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
WO2022015573A2 (en) 2020-07-13 2022-01-20 President And Fellows Of Harvard College Sars-cov-2 antigen-binding proteins and uses thereof
WO2022026475A2 (en) 2020-07-27 2022-02-03 Igm Biosciences, Inc. Multimeric coronavirus binding molecules and uses thereof
WO2022046888A1 (en) 2020-08-25 2022-03-03 Target Discovery Merger Sub II, LLC Sars-cov-2 associated antibody compositions and methods of use
CN116528897A (zh) 2020-08-26 2023-08-01 旗舰开拓创新六世公司 靶向SARS-CoV-2的抗原结合分子
KR20230127305A (ko) 2020-12-29 2023-08-31 발-첨, 리미티드 파트너십 Covid-19에 대한 중화 단일클론 항체
WO2022159685A2 (en) 2021-01-22 2022-07-28 Vanderbilt University Sars-cov-2 coronavirus antibodies and uses thereof
WO2022204202A1 (en) 2021-03-23 2022-09-29 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
KR20240035758A (ko) 2021-05-24 2024-03-18 비르 바이오테크놀로지, 인코포레이티드 조작된 폴리펩타이드
WO2022271863A1 (en) 2021-06-23 2022-12-29 Chan Zuckerberg Biohub, Inc. Coronavirus neutralizing compositions and associated methods
WO2023028603A2 (en) 2021-08-27 2023-03-02 Humabs Biomed Sa Engineered compositions
EP4147716A1 (en) 2021-09-10 2023-03-15 Samatva Research Corporation Anti-virus moiety immobilised in a matrix
EP4519310A1 (en) 2022-05-06 2025-03-12 Generate Biomedicines, Inc. Antigen binding molecules targeting sars-cov-2

Also Published As

Publication number Publication date
KR20230035350A (ko) 2023-03-13
IL299630A (en) 2023-03-01
US20230295275A1 (en) 2023-09-21
JP2023534923A (ja) 2023-08-15
WO2022010921A1 (en) 2022-01-13
EP4175983A1 (en) 2023-05-10
CA3183367A1 (en) 2022-01-13
US11981725B2 (en) 2024-05-14

Similar Documents

Publication Publication Date Title
US11981725B2 (en) Antigen binding molecules targeting SARS-CoV-2
US11987616B2 (en) Antigen binding molecules targeting SARS-CoV-2
US12473560B2 (en) Antigen binding molecules targeting SARS-CoV-2
CN109310756B (zh) 新型血管生成素2，vegf双特异性拮抗剂
AU2014273966B2 (en) Oncostatin M receptor antigen binding proteins
US20250145690A1 (en) Human monoclonal antibodies that broadly target coronaviruses
KR20170138494A (ko) 항-ｔｙｒ０３ 항체 및 이의 용도
KR102748987B1 (ko) 사스-코로나바이러스-2에 특이적으로 결합하는 항체 및 그의 용도
KR20250152073A (ko) 항체, 항원 결합 단편 및 사용 방법
US11186632B2 (en) Methods of treating cancer using bifunctional molecules that target growth factors
KR20220007128A (ko) 항-ｓｅｍａ３ａ 항체 및 눈 또는 안구 질환 치료를 위한 이의 용도
US20230242623A1 (en) Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection
KR20220117267A (ko) Tgf-베타-rii 결합 단백질
KR20150140752A (ko) M-csf를 표적으로 하는 항체
US11359007B2 (en) Anti-SARS-CoV-2 neutralizing antibodies
WO2022198040A1 (en) Antibodies specific to sialic acid-binding ig-like lectin 15 and uses thereof
CN116635410A (zh) 靶向SARS-CoV-2的抗原结合分子
CN116547005A (zh) 靶向SARS-CoV-2的抗原结合分子
US20240043506A1 (en) Sars-cov-2 antibodies
WO2023012314A1 (en) Anti-plexin-b1 antibodies
EA046745B1 (ru) Способ лечения рака активируемым антителом против pdl1

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF A CO-INVENTOR TO READ RAMOS, ALEXIS HIRAM